TG Therapeutics director sells 5,000 shares

TG Therapeutics director Laurence N. Charney reported a 5,000-share tax-related sale on September 10, 2026, retaining 168,640 shares afterward.

Rhea-AI Filing Summary

TG THERAPEUTICS, INC. (TGTX) director Laurence N. Charney reported a sale of 5,000 shares of Common Stock on September 10, 2026. According to the filing, the Company’s restricted stock administrator sold these shares to satisfy Mr. Charney’s income tax obligations, at a volume-weighted average price of $54.96 per share.

After this tax-related sale, Mr. Charney held 168,640 shares directly, including restricted Common Stock that vests over various time periods. No transactions were reported under a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Seller: 5,000 shares

Net Sell 1 txn

Insider Charney Laurence N

Role Director

Sold 5,000 shs ($275K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F3	5,000	$54.96	$275K

Holdings After Transaction: Common Stock — 168,640 shares (Direct)

Footnotes (3)

1. F1. These shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Charney's income tax obligations.
2. F2. Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $54.92 to $54.99. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. Includes shares of restricted Common Stock, which vest over various time periods.

Key Figures

Shares sold: 5,000 shares Volume weighted average price: $54.96 per share Price range: $54.92–$54.99 per share +1 more

4 metrics

Shares sold 5,000 shares Common Stock sold on September 10, 2026 to satisfy income tax obligations

Volume weighted average price $54.96 per share Average sale price for transactions between $54.92 and $54.99 on September 10, 2026

Price range $54.92–$54.99 per share Range of prices for all transactions included in the VWAP on the sale date

Shares held after transaction 168,640 shares Total direct holdings of Laurence N. Charney after the September 10, 2026 sale

Key Terms

volume weighted average price, restricted Common Stock, income tax obligations

3 terms

volume weighted average price financial

"Price is the volume weighted average price of all transactions made"

The volume weighted average price (VWAP) is a way to measure the average price of a security, such as a stock, over a specific period, taking into account how many units were traded at each price. It’s similar to calculating the average cost of items bought when some are more frequently purchased than others. Investors use VWAP to assess whether a security is being bought or sold at a fair price during trading.

restricted Common Stock financial

"Includes shares of restricted Common Stock, which vest over"

Restricted common stock is company shares that carry limits on selling or transferring for a set period or until certain conditions are met, like time-based vesting or regulatory clearance. Think of them as shares in a locked box that gradually open; they can become freely tradable later but initially reduce the number of shares available on the market. Investors watch restricted stock because its eventual release can change a company’s share supply, affect stock price, and influence control and dilution.

income tax obligations financial

"sold by the Company's restricted stock administrator in order to satisfy"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TGTX director Laurence N. Charney report?

Laurence N. Charney reported a sale of 5,000 shares of TG THERAPEUTICS, INC. Common Stock on September 10, 2026. The shares were sold by the Company’s restricted stock administrator to satisfy his income tax obligations.

At what price were the TGTX shares sold in this Form 4 filing?

The 5,000 TG THERAPEUTICS, INC. shares were sold at a volume weighted average price of $54.96 per share, based on trades executed between $54.92 and $54.99 on September 10, 2026.

How many TGTX shares does Laurence N. Charney hold after the reported sale?

Following the reported sale, Laurence N. Charney directly holds 168,640 shares of TG THERAPEUTICS, INC. Common Stock. This total includes restricted Common Stock that vests over various time periods.

Was the TGTX insider sale made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates that no Rule 10b5-1 trading plan is reported for this transaction. The shares were sold by the Company’s restricted stock administrator to cover Mr. Charney’s income tax obligations.

Is the 5,000-share TGTX sale a discretionary sale by the director?

The filing states that the 5,000 shares were sold by the Company’s restricted stock administrator in order to satisfy income tax obligations for Laurence N. Charney, indicating the transaction was tax-related rather than a discretionary open-market sale by him.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 05:03 PM Accepted by SEC EDGAR 09/14/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Charney Laurence N

(Last) (First) (Middle)

3020 CARRINGTON MILL BLVD, SUITE 475

(Street)

MORRISVILLE NORTH CAROLINA 27560

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TG THERAPEUTICS, INC. [ TGTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2026		S		5,000(1)	D	$54.96(2)	168,640(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Charney's income tax obligations.

2. Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $54.92 to $54.99. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. Includes shares of restricted Common Stock, which vest over various time periods.

	/s/ Laurence N. Charney	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)